Table 1 Baseline characteristics of patients infected without and with extended-spectrum beta-lactamase (ESBL)-Enterobacterales
Cases (N = 51) | Controls (N = 51) | |
|---|---|---|
Male, N (%) | 28 (54.9%) | 17 (33.3%) |
Age at time of infection, mean (SD) | 54.8 (12) | 53.4 (14.8) |
Transplanted organ (matched variable) | ||
Kidney | 33 (64.7%) | 33 (64.7%) |
Kidney-pancreas | 4 (7.8%) | 4 (7.8%) |
Liver (incl kidney-liver) | 9 (17.6%) | 9 (17.6%) |
Heart | 5 (9.8%) | 5 (9.8%) |
BMI at transplantation, mean (SD) | 25.5 (4.1) | 25.1 (4.2) |
Caucasian ethnicity, N (%) | 46 (90.2%) | 49 (96.1%) |
Comorbidities, N (%) | ||
Cardiopulmonary disease | 27 (52.9%) | 25 (49%) |
Metabolic/endocrine disease | 35 (68.6%) | 43 (84.3%) |
Cancer | 8 (15.7%) | 6 (11.8%) |
Other | 32 (62.7%) | 31 (60.8%) |
Previously documented ESBL colonizationa | 19 (37%) | 0 (0%) |
Antibioticsb (30 days before infection), N (%) | 24 (47.1%) | 14 (27.5%) |
BL/BLI | 10 (37%) | 6 (28.6%) |
Carbapenem | 6 (22.2%) | 3 (14.3%) |
Quinolone | 10 (37%) | 3 (14.3%) |
Cephalosporine | 7 (25.9%) | 0 (0%) |
Sulfamethoxazol/trimethoprim | 7 (25.9%) | 4 (19%) |
Hospital-onset, N (%) | 20 (39.2%) | 19 (37.3) |
Day of onset (median, IQR) | 20 (9.5–60) | 8 (6–42) |
Days from transplantation to infection, median (IQR) | 67 (24–228) | 71 (33–227) |
Year of 1st infection, N (%) | ||
2012 | 6 (11.8%) | 8 (15.7%) |
2013 | 9 (17.6%) | 13 (25.5%) |
2014 | 14 (27.5%) | 12 (23.5%) |
2015 | 16 (31.4%) | 10 (19.6%) |
2016 | 6 (11.8%) | 8 (15.7%) |
Infection site, N (%) | ||
Urinary tract | 38 (74.5%) | 39 (76.5%) |
With bacteremia | 5 (13.2%) | 10 (25.6%) |
Abdominal/liver | 2 (3.9%) | 3 (5.9%) |
Respiratory tract | 3 (5.9%) | 5 (9.8%) |
Surgical site | 3 (5.9%) | 4 (7.8%) |
Primary bacteremia | 2 (3.9%) | 1 (2.0%) |
Other | 3 (5.9%) | 1 (2.0%) |
If urinary tract infection, N (%) | ||
Obstruction | 2/38 (5.3%) | 5/39 (12.8%) |
Catheter | 12/38 (31.6%) | 17/39 (43.6%) |